Meso
55 programs · 55 companies
Programs
55
Companies
55
Trials
42
MOAs
39
PI3KiKRASG12CiPARPiALKiJAK1/2iEGFRiCGRPantEZH2iPRMT5iAuroraAi
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Preclinical | SGLT2 | ||
| Terasacituzumab | NDA/BLA | IL-23 | ||
| GSK-6516 | Phase 1/2 | MALT1 | ||
| Zanuratamab | Phase 1/2 | CDK2 | ||
| Niramavacamten | Phase 2 | SGLT2 | ||
| 207-2754 | Phase 1/2 | KRASG12D | ||
| MDG-4513 | Phase 1/2 | CD3 | ||
| Liratinib | NDA/BLA | TIM-3 | ||
| Zanurapivir | Phase 1 | SOS1 | ||
| RXR-1394 | Phase 3 | BET | ||
| Lisoinavolisib | Approved | TIGIT | ||
| EXA-4696 | Phase 2/3 | KRASG12C | ||
| TLX-9288 | Phase 2 | CD123 | ||
| Zenozumab | Phase 3 | PI3Kα | ||
| Zorinesiran | Phase 2/3 | JAK2 | ||
| IPS-9466 | NDA/BLA | TROP-2 | ||
| Terazasiran | Phase 2 | TROP-2 | ||
| Polamavacamten | Phase 2 | LAG-3 | ||
| INH-3643 | NDA/BLA | CD20 | ||
| Tiralucimab | Phase 2 | TNFα | ||
| APT-892 | Approved | PD-1 | ||
| SPI-1775 | Preclinical | PD-1 | ||
| AVE-4742 | Phase 1 | C5 | ||
| Zanuinavolisib | Phase 2 | ALK | ||
| Ribomavacamten | Phase 3 | EZH2 | ||
| BCY-3228 | Preclinical | GIP-R | ||
| Tezesotorasib | Phase 2/3 | DLL3 | ||
| Tixacilimab | Phase 1/2 | FcRn | ||
| Zanutapinarof | Approved | HER2 | ||
| Ribotinib | Phase 1/2 | CD20 | ||
| Talafotisoran | NDA/BLA | PRMT5 | ||
| FLA-5216 | Approved | CD47 | ||
| Pemifotisoran | Phase 1/2 | CDK4/6 | ||
| Lisosertib | Phase 1 | CD3 | ||
| Rimanaritide | Phase 3 | CFTR | ||
| KOD-8391 | Phase 2/3 | PARP | ||
| NTR-8128 | Phase 3 | Nectin-4 | ||
| Motafutibatinib | Approved | KIF18A | ||
| 051-2746 | Phase 2/3 | CFTR | ||
| MOR-1300 | Phase 1/2 | EZH2 | ||
| MRK-9679 | NDA/BLA | Menin | ||
| Gozesertib | Phase 1/2 | CDK2 | ||
| TWS-2496 | Phase 2/3 | CD47 | ||
| MYG-2072 | Phase 2 | Aβ | ||
| Bemazumab | Phase 2/3 | IL-17A | ||
| FER-3003 | Phase 1/2 | FXIa | ||
| Cevisacituzumab | Preclinical | GLP-1R | ||
| Doxacagene | Approved | KRASG12C | ||
| TES-326 | Approved | Tau | ||
| ACH-2340 | Phase 3 | CDK4/6 | ||
| VIN-1694 | Approved | AuroraA | ||
| SIR-IIT-682 | Preclinical | Menin | ||
| WAT-1779 | Phase 1 | KRASG12D | ||
| Fixatenlimab | NDA/BLA | MALT1 | ||
| Semazasiran | NDA/BLA | IL-23 |
Trials (42)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT04020868 | Tiramavacamten | Preclinical | Completed |
| NCT04398615 | Zanuratamab | Phase 1/2 | Active |
| NCT08142378 | Niramavacamten | Phase 2 | Completed |
| NCT05549249 | 207-2754 | Phase 1/2 | Active |
| NCT07725954 | Liratinib | NDA/BLA | Terminated |
| NCT05658977 | Zanurapivir | Phase 1 | Active |
| NCT08526031 | RXR-1394 | Phase 3 | Active |
| NCT03774341 | TLX-9288 | Phase 2 | Active |
| NCT06274601 | Zenozumab | Phase 3 | Terminated |
| NCT03217716 | APT-892 | Approved | Terminated |
| NCT05164390 | APT-892 | Approved | Terminated |
| NCT04823126 | Zanuinavolisib | Phase 2 | Active |
| NCT08519248 | Zanuinavolisib | Phase 2 | Recruiting |
| NCT08590892 | Ribomavacamten | Phase 3 | Recruiting |
| NCT07964391 | BCY-3228 | Preclinical | Not yet recr... |
| NCT03142376 | BCY-3228 | Preclinical | Completed |
| NCT05988314 | Tezesotorasib | Phase 2/3 | Not yet recr... |
| NCT08557954 | Tezesotorasib | Phase 2/3 | Completed |
| NCT05642214 | Zanutapinarof | Approved | Not yet recr... |
| NCT06270666 | Ribotinib | Phase 1/2 | Terminated |